Business
Todos Medical to Present at the Benzinga Global Small Cap Conference
Todos Medical to Present at the Benzinga Global Small Cap Conference.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n New York, NY, and Tel Aviv, ISRAEL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CEO Gerald Commissiong will be presenting a corporate overview at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021. The event bridges the gap between small cap companies, investors and traders. SESSION DETAILS WHAT: October Small Cap Conference - Todos Medical WHEN: 1:55 PM/ET - October 28 WHERE: FREE ticket at https://www.benzinga.com/events/small-cap/ “With the upcoming interim data read out expected this quarter from our ongoing Phase 2 clinical trial evaluating the safety and efficacy of Tollovir® in treating hospitalized COVID-19 patients currently ongoing in Israel, conducted together with our joint venture partners NLC Pharma, we are very excited about what the near-term future holds for Todos Medical,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Tollovir is an Mpro (Main protease, 3CL protease or 3CLpro) inhibitor that has high binding affinity to the Mpro receptor, low cross reactivity with other receptors in the human body, as well as strong anti-cytokine activity that potentially makes it an ideal therapeutic candidate for the treatment of COVID-19 at all stages of disease from prevention to late-stage hospitalization. With the recent publication in Nature Neuroscience of key data identifying for the first time that Mpro is potentially the main driver of brain-related COVID-19 symptoms such as ‘Brain Fog’ and memory loss, and emerging evidence that Mpro downregulates immune responses to SARS-CoV-2 infection in the brain and elsewhere in peripheral vascular tissues that could potentially explain the diversity of immune response, we believe it is now becoming more important than ever to focus on the development of Tollovir as a potentially game-changing treatment for COVID-19 patients.” For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com. About Todos Medical Ltd. Founded in Rehovot, Israel with...